BioVie, an early stage biotech developing therapies for cirrhosis, postponed its IPO on Monday. It had filed to raise $15 million by offering 1.3 million shares based on a price of $11.44, the as-converted last close of its shares on the OTC (BIVI).
The Los Angeles, CA-based company was founded in 2013 and had planned to list on the Nasdaq under the symbol BIVI. ThinkEquity was set to be the sole bookrunner on the deal.
